Patents Examined by Aurora M Fontainhas
  • Patent number: 11123411
    Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins). In some embodiments, the disclosed formulations also include one or more anti-VEGF agents. The disclosed formulations may be applied to an intraocular or extraocular region of a patient.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: September 21, 2021
    Inventor: Gary E. Borodic
  • Patent number: 11123412
    Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins. In some embodiments, the disclosed formulations are applied to the para orbital or periorbital region of a patient to delay or stop the progression of dry macular degeneration. The methods described herein do not involve a direct injection into the eye or subconjunctival region, thus significantly easing both comfort and administration related complications and further preserving barrier functions of retinal layers while also delaying or ceasing the degenerative process to wet conversion.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 21, 2021
    Inventor: Gary E. Borodic
  • Patent number: 11098108
    Abstract: A monoclonal antibody that binds ?-synuclein, and that binds tau fibrils, and methods of using the monoclonal antibody, are provided. The monoclonal antibody may be hybridoma clone 2F11. Also provided is a composition comprising the monoclonal antibody 2F11 and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient. A method of reducing active ?-synuclein in a subject in need thereof is also disclosed. The method involves administering an amount of the composition comprising 2F11 to the subject. The monoclonal antibody 2F11 may also be used to determine the ?-synuclein, or tau fibril, level in a biological sample.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 24, 2021
    Inventor: Ariel Louwrier
  • Patent number: 11096993
    Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin. The disclosed formulations may be applied to an intraocular or extraocular region of a patient. If applied to an extra ocular region of a patient, the botulinum-based pharmaceutical formulation may then be transported to the intra-ocular region of the patient, allowing the active ingredient(s) to penetrate into the choroid, neuro-retina, and/or retinal pigment epithelium without direct injection into the eye, eliminating risk of retinal detachment, retinal break, retinal hemorrhage, and blindness. The methods described herein allow for increased blood flow to the choroid, which improves removal of metabolites and intra retinal fluid and also serves to arrest, reverse and/or delay early and later stages of age-related macular degeneration.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 24, 2021
    Inventor: Gary E. Borodic
  • Patent number: 11091552
    Abstract: A specific binding molecule is provided which binds to galectin-3 protein, methods of their production and methods of use.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: August 17, 2021
    Assignees: LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE BORDEAUX
    Inventors: Alexandre Fontayne, Philippe Mondon, Jeanny Laroche-Traineau, Marie-Josée Jacobin-Valat, Martine Cérutti, Gisèle Clofent-Sanchez, Cyril Lorenzato, Audrey Hémadou
  • Patent number: 11078271
    Abstract: An object of the present invention is to provide a monoclonal antibody that recognizes an extracellular region of Claudin-2. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: August 3, 2021
    Assignee: Osaka University
    Inventors: Masuo Kondoh, Kiyohito Yagi, Akihiro Watari, Masayoshi Fukasawa, Minoru Tada, Jun Kunisawa
  • Patent number: 11053313
    Abstract: An object of the present invention is to provide a novel molecule which has high specificity to CLDN-5 and recognizes an extracellular domain of CLDN-5. The object is achieved by an antibody which specifically recognizes a three-dimensional structure or a primary structure of an extracellular domain of a Claudin-5 protein.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 6, 2021
    Assignees: OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY, FUJIFILM WAKO PURE CHEMICAL CORPORATION
    Inventors: Masuo Kondoh, Kiyohito Yagi, Takefumi Doi, Yoshiaki Okada, Yosuke Hashimoto, Tatsuya Sawasaki, Hiroyuki Takeda, Kohki Endo, Maki Tamura
  • Patent number: 11028158
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 8, 2021
    Assignees: Prothena Biosciences Limited, University Health Network
    Inventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Patent number: 11020359
    Abstract: The present invention relates to novel nanomaterial-molecular compositions, methods and devices thereof for efficient and targeted trans-differentiation of cells including fibroblasts and glia into neurons, both in vitro as well as in situ and in-vivo, which is of great importance for cell replacement therapies. Specifically, the invention provides a nanomaterial-molecular composition, device and method for targeted nano-enhanced opto-chemical trans-differentiation of fibroblasts/glia to neurons in the central and peripheral nervous system for restoration of neural functions in patients by delivery of nanomaterial-molecular composition, followed by optical illumination.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: June 1, 2021
    Assignee: Nanoscope Technologies LLC
    Inventor: Samarendra Kumar Mohanty
  • Patent number: 10995137
    Abstract: The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and their tau binding fragments in the treatment of retinoid amyloidosis, age related macular degeneration (ARMD), and glaucoma.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: May 4, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist
  • Patent number: 10995141
    Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
    Type: Grant
    Filed: April 19, 2020
    Date of Patent: May 4, 2021
    Assignees: ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
    Inventors: Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
  • Patent number: 10980879
    Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: April 20, 2021
    Assignee: SYKEHUSET SØRLANDET HF
    Inventors: Christian Kersten, Marte Grønlie Cameron, Svein Mjåland
  • Patent number: 10961302
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 30, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Patent number: 10954292
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: March 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Patent number: 10946064
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 16, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
  • Patent number: 10947302
    Abstract: In alternative embodiments, provided are compositions such as antibodies, e.g., single chain antibodies, that target 3-repeat (3R) Tau for the treatment of neurodegenerative disorders and taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation, and methods for making and using them. In alternative embodiments, provided are brain-penetrating antibodies that specifically recognize 3R Tau, and methods of using them to treat, ameliorate, prevent or decrease the symptoms of neurodegenerative disorders including taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: March 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Eliezer Masliah, Brian Spencer, Edward Rockenstein
  • Patent number: 10927167
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: February 23, 2021
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Patent number: 10914749
    Abstract: The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method comprises the steps of (a) reducing heterocomplexes comprising NPTX1 and NPTX2 present in a biological sample obtained from the patient into NPTX1 and NPTX2 monomers; (b) covalently modifying the thiol groups of the NPTX1 and NPTX2 monomers to prevent re-formation of NPTX1/NPTX2 heterocomplexes; (c) detecting NPTX2 in the sample; and (d) assessing cognitive function in the patient by comparing NPTX2 detected in the sample to a control.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: February 9, 2021
    Assignee: The Johns Hopkins University
    Inventors: Paul F. Worley, DeSheng Xu, Meifang Xiao
  • Patent number: 10906967
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: February 2, 2021
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Patent number: 10889639
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom